Burlington, MA and Salem, NH
March 23, 2026
Chrysalis Services, LLC and bioX, LLC today announced a strategic partnership that is designed to accelerate innovative GMP execution while ensuring accessibility and affordability. The collaboration combines bioX’s analytical development, process optimization and engineering expertise with Chrysalis’ unique operational services platform and GMP facility infrastructure. This reflects both organizations’ commitment to democratizing access for emerging and established companies in the biopharma space.
“Chrysalis was built as a streamlined infrastructure and services platform for GMP execution that reduces barriers to innovation. Our operating model provides innovators with operationalized GMP infrastructure, without the burden of significant capital investment and operational expenses. This collaboration with bioX enhances our services, and brings valuable analytical testing, process development and process optimization expertise to our customers,” said Sarah Stevens, Chief Executive Officer of Chrysalis. “We are delighted to partner with the exceptional experience and expertise that Mark and his bioX team bring.”
True to the Chrysalis operating model, customers from early development through commercial manufacturing will retain full ownership of their process, product, and manufacturing schedule.
On the partnership, bioX CEO Mark McElligott states, “We share a vision with Chrysalis to accelerate development and production of life-saving therapeutics – from niche rare disease products to larger scale commercial manufacturing where COGS are critical. Partnering with Chrysalis allows us to bring our services and expertise to more companies earlier in the process. Together, we are enabling a smoother and more efficient progression from the lab bench to manufacturing.”
Make it yours
Choose your equipment, choose your layout, choose your services. Make yourself at home in a space designed for you.
